The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 7, 1996, Pages 288-292

  Fassos, F F ^a   Klein, J ^a   Fernandes, D ^a   Matsui, D ^a   Olivieri, N F ^a   Koren, G ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

1,2 dimethyl 3 hydroxypyrid 4 one (L1); Deferiprone; Iron chelation; Oral iron chelator; Thalassemia; Urinary iron excretion

Indexed keywords

DEFERIPRONE; HEMOGLOBIN; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IRON CHELATION; URINE LEVEL;

ADOLESCENT; ADULT; AREA UNDER CURVE; ERYTHROCYTE TRANSFUSION; HALF-LIFE; HEMOGLOBINS; HUMANS; IRON; IRON CHELATING AGENTS; PYRIDONES; SPECTROPHOTOMETRY, ATOMIC; THALASSEMIA;

EID: 0030018410     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Barry M, Flynn D, Letsky E, Risdon R 1974 Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress. Br Med J 2: 16-24
2. Bronspiegel-Weintrob N, Olivieri NF, Tyler BJ, Andrews DF, Freedman MH, Holland FJ 1990 Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 323: 713-719
3. Cohen AR, Martin M, Schwartz E 1984 Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 58: 369-373
4. Collins AF, Fassos F, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF 1994 Iron balance and dose response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded patients with sickle cell disease. Blood 83: 2329-2333
5. D'Argenio DZ, Schumitiky A 1979 A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 9: 115-134
6. Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G 1994 Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β-thalassemia. Clin Pharmacol Ther 55: 70-75
7. Fosburg M, Nathan DG 1990 Treatment of Cooley's anemia. Blood 76: 435-444
8. Henry RJ, Cannon DC, Winkelman JW 1974 Quick index to methods and normal values. In: Henry RJ, Cannon DC, Winkelman JW (eds) : Clinical Chemistry: Principles and Techniques. Harper and Row, New York, inside cover
9. Klein J, Damani LA, Cheung D Epemoulu O, Olivieri N, Koren G 1991 An HPLC method for the measurement of the iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in human plasma. Ther Drug Monit 13: 51-54
10. Kontoghiorghes GJ, Sheppard L 1989 Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-metnylpyrid-4-ones. Inorg Chim Acta 136:L11-12
11. Matsui D, Klein J, Hermann C, Grunau V, McClelland R, Chung D, St. Louis P, Olivieri N, Koren G 1991 Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 50: 294-298
12. Pippard MJ, Callender ST, Finch CA 1982 Ferrioxamine excretion in iron loaded man. Blood 60: 288-294
13. Scully RE, McNeely BU, Mark EJ 1986 Normal reference laboratory values. N Engl J Med 314: 39-49
14. Wolfe LC, Olivieri NF, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan G 1985 Prevention of cardiac disease with subcutaneous desferroxamine in patients with thalassemia major. N Engl J Med 312: 1600-1603
15. Zurlo MG, De Stefano P, Borgna-Pignalli C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S 1989 Survival and causes of death in thalassemia major. Lancet II: 27-30